Acute Pain Management & Opioid Principles
A Step 2 CK–focused walkthrough of acute pain management: multimodal, opioid-sparing analgesia; the stepwise WHO-adapted algorithm (matched to severity and stepped down for acute pain); safe opioid selection including renal failure; and recognizing/reversing opioid toxicity — anchored on the next best step in management.
Principles of Acute Pain Management
Modern acute pain care is multimodal and opioid-sparing: assess the pain, build a non-opioid base, and add opioids only for moderate-to-severe pain using the lowest effective dose of an immediate-release agent for the shortest duration. Combining mechanisms (acetaminophen + NSAID + opioid ± adjuvant or a regional block) controls pain while cutting opioid requirements and side effects. On Step 2 CK the recurring tasks are: pick the next agent by severity, choose the safe opioid in organ dysfunction, and recognize and reverse opioid toxicity. Uncontrolled acute pain and reflexive over-opioidization are both wrong answers — the exam rewards a titrated, stepwise plan.
- Multimodal analgesia is standard: scheduled acetaminophen ± NSAID as the base, add an opioid only for moderate–severe pain
- Non-opioids first for mild pain; acetaminophen ≤4 g/day (≤2–3 g/day in elderly, liver disease, or heavy alcohol use)
- Use immediate-release opioids for acute pain — never start a long-acting/ER opioid or fentanyl patch in an opioid-naive patient
- Start low, titrate to effect; monitor RR and sedation because sedation precedes respiratory depression
- Co-prescribe a stimulant laxative (senna) — tolerance never develops to opioid-induced constipation (docusate alone is inadequate)
- Avoid meperidine (neurotoxic normeperidine → seizures) and avoid morphine/codeine in renal failure (active metabolites accumulate)
- Codeine and tramadol are CYP2D6 prodrugs — avoid in children (post-tonsillectomy deaths) and while breastfeeding
- Do not withhold analgesia in the acute abdomen — it does not mask the surgical diagnosis
- Limit acute opioid courses (typically 3–7 days), reassess, and counsel on safe storage/disposal
Stepwise Approach (WHO Ladder, Adapted for Acute Pain)
| Step | Pain (0–10) | Preferred agents | Key notes |
|---|---|---|---|
| 1 – Mild | 1–3 | Acetaminophen ± NSAID | Non-opioid base; add adjuvant (e.g., gabapentinoid) if neuropathic |
| 2 – Moderate | 4–6 | Non-opioid + low-potency/low-dose opioid (tramadol, low-dose oxycodone) | Keep acetaminophen/NSAID scheduled around the clock |
| 3 – Severe | 7–10 | Non-opioid + strong opioid (morphine, hydromorphone); IV titration or PCA | Add regional block or ketamine if refractory. For acute pain, match severity from the start and step down as pain resolves (reverse ladder) rather than climbing from step 1 |
Opioid Selection & Key Cautions
| Opioid | Use / pearl | Caution |
|---|---|---|
| Morphine | Prototype strong opioid; PO:IV ≈ 3:1 | Renally-cleared active metabolites accumulate in renal failure — M3G drives neuroexcitation (myoclonus, delirium, hyperalgesia); M6G drives prolonged sedation/respiratory depression |
| Hydromorphone | Potent alternative when morphine poorly tolerated | Neuroexcitatory metabolite (H3G) accumulates — dose-reduce in severe CKD |
| Fentanyl | Preferred in renal failure; rapid IV onset, inactive metabolites | Transdermal patch only for stable chronic pain — never acute or opioid-naive |
| Oxycodone | Reliable oral option | Active metabolites can accumulate in renal failure; combination pills capped by the acetaminophen ceiling |
| Codeine / tramadol | Weak; CYP2D6 prodrugs | Unpredictable effect; avoid in children & breastfeeding; tramadol is serotonergic and lowers the seizure threshold |
| Meperidine | Avoid | Normeperidine → seizures; serotonin syndrome with MAOIs/SSRIs |
| Methadone | Long-acting; specialist use | QT prolongation; long, variable half-life |
Vignette: A 70-year-old man with CKD (eGFR 18) on scheduled IV morphine for a hip fracture becomes progressively confused with muscle twitching (myoclonus) on hospital day 2. Pupils are pinpoint, but RR is 16 and SpO₂ is normal.
Next best step: Stop morphine and rotate to fentanyl (or dose-reduced hydromorphone). Morphine's renally-cleared active metabolites accumulate in renal failure and cause neuroexcitation/delirium. Reserve naloxone for true respiratory depression — not isolated myoclonus. When rotating opioids, reduce the equianalgesic dose by 25–50% to account for incomplete cross-tolerance.
Vignette: Two hours after starting a morphine PCA, a post-op patient is difficult to arouse: RR 6, SpO₂ 84%, pinpoint pupils.
Next best step: Stop the opioid, support ventilation (O₂ / bag-mask), and give titrated low-dose IV naloxone (e.g., 0.04–0.4 mg, repeated every 2–3 min) to restore adequate breathing — not full alertness, which can precipitate withdrawal and severe pain. Because naloxone's half-life is shorter than most opioids, watch for re-sedation and consider repeat doses or an infusion. Recall that sedation precedes respiratory depression, so a rising sedation score is the earliest warning.
OPQRST — assess any pain: Onset, Provocation/palliation, Quality, Region/radiation, Severity, Timing.
Opioid toxidrome triad: CNS depression + respiratory depression + miosis (pinpoint pupils). Respiratory depression is the killer; naloxone reverses it. Tolerance develops to most opioid effects except constipation and miosis — which is why a bowel regimen is mandatory.
Special Situations & Pitfalls
- Sickle cell vaso-occlusive crisis: treat as an emergency with prompt, individualized IV opioids (often PCA) plus non-opioids and hydration — do not undertreat, and avoid meperidine.
- On buprenorphine or methadone maintenance: continue the maintenance dose and add additional multimodal/short-acting analgesia; stopping maintenance is a classic wrong answer.
- Acute abdomen: give analgesia — it does not obscure the surgical diagnosis.
- NSAID cautions: avoid in significant CKD, active GI bleed/peptic ulcer, and decompensated heart failure; weigh cardiovascular risk.
- Opioid stewardship: prescribe the lowest effective immediate-release dose for the shortest course (often 3–7 days for acute pain), reassess, counsel on safe storage/disposal, and consider co-prescribing naloxone for higher-risk patients.
Practice Clinical Management now
Board-style questions, spaced-repetition flashcards, and a Socratic AI tutor — free to start.